Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer
Open Access
- 21 November 2006
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 95 (11), 1555-1561
- https://doi.org/10.1038/sj.bjc.6603477
Abstract
Indoleamine 2,3-dioxygenase (IDO) is a tryptophan-catabolising enzyme inducing immune tolerance. The present study aimed to investigate IDO expression and its prognostic significance in endometrial cancer. Indoleamine 2,3-dioxygenase expression in endometrial cancer tissues (n=80) was immunohistochemically scored as four groups (IDO−, 1+, 2+, and 3+). The high IDO expression (IDO2+ or 3+) in tumour cells was found in 37 (46.3%) of the 80 cases, and was positively correlated with surgical stage, myometrial invasion, lymph-vascular space involvement, and lymph node metastasis, but not with the histological grade. Patients with high IDO expression had significantly impaired overall survival and progression-free survival (PFS) (P=0.002 and P=0.001, respectively) compared to patients with no or weak expression of IDO (IDO− or 1+). The 5-year PFS for IDO−/1+, 2+, and 3+ were 97.7, 72.9, and 36.4%, respectively. Even in patients with early-stage disease (International Federation of Gynecology and Obstetrics I/II, n=64), the PFS for IDO2+ /3+ was significantly poor (P=0.001) compared to that for IDO−/1+. On multivariate analysis, IDO expression was an independent prognostic factor for PFS (P=0.020). These results indicated that the high IDO expression was involved in the progression of endometrial cancer and correlated with the impaired clinical outcome, suggesting that IDO is a novel and reliable prognostic indicator for endometrial cancer.Keywords
This publication has 31 references indexed in Scilit:
- Tryptophan degradation in patients with gynecological cancer correlates with immune activationCancer Letters, 2005
- Stratification of Intermediate-Risk Endometrial Cancer Patients into Groups at High Risk or Low Risk for Recurrence Based on Tumor Gene Expression ProfilesClinical Cancer Research, 2005
- Ido expression by dendritic cells: tolerance and tryptophan catabolismNature Reviews Immunology, 2004
- Prognostic Significance of E-Cadherin Protein Expression in Pathological Stage I-III Endometrial CancerClinical Cancer Research, 2004
- Expression of Placental Leucine Aminopeptidase Is Associated with a Poor Outcome in Endometrial Endometrioid AdenocarcinomaOncology, 2004
- Prognostic Impact of Alterations in P-Cadherin Expression and Related Cell Adhesion Markers in Endometrial CancerJournal of Clinical Oncology, 2004
- A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group studyGynecologic Oncology, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejectionInternational Journal of Cancer, 2002
- Localization of indoleamine 2,3-dioxygenase in human female reproductive organs and the placentaMolecular Human Reproduction, 2002